Background: Previous studies have examined the relation between postmenopausal estrogen replacement therapy (ERT) and the risk of Alzheimer disease (AD). The findings have been inconsistent, since some studies have been interpreted as showing a protective effect while others have reported no effect.
Objective: To determine whether exposure to ERT is associated with a reduced risk of AD.
Design: Population-based nested case-control study.
Setting: The United Kingdom-based General Practice Research Database.
Patients: The base cohort consisted of women who were recipients of ERT (n = 112 481) and a similar cohort of women who did not use estrogens (n = 108 925). The 2 cohorts were restricted to women born on or before January 1, 1950. From the 2 cohorts, we identified and verified 59 newly diagnosed cases of AD and 221 matched control subjects.
Main Outcome Measure: Prior and current use of ERT in cases compared with controls.
Results: Among the 59 newly diagnosed cases of AD, 15 (25%) were current estrogen users, while among the controls, 53 (24%) were current users. The adjusted odds ratio comparing all current estrogen recipients with nonrecipients was 1.18 (95% confidence interval, 0.59-2.37). In estrogen users who took the drug for 5 years or longer compared with nonusers, the odds ratio was 1.05 (95% confidence interval, 0.32-3.44). Odds ratios were similar for estrogen recipients who received estrogens alone and recipients who received combined estrogen-progestin treatment.
Conclusion: The use of ERT in women after the onset of menopause was not associated with a reduced risk of developing AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archneur.58.3.435 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Post-menopausal women experience more severe muscular fatty infiltration, though the mechanisms remain unclear. The decline in estrogen levels is considered as a critical physiological alteration during post-menopause. Fibro/adipogenic progenitors (FAPs) are identified as major contributors to muscular fatty infiltration.
View Article and Find Full Text PDFRisk factors for coronary atherosclerotic heart disease in postmenopausal women: a meta-analysis.
Front Cardiovasc Med
January 2025
Department of Nursing, School of Medical and Health Engineering, Changzhou University, Changzhou, Jiangsu, China.
Background: Coronary atherosclerotic heart disease (coronary heart disease; CHD) is the leading cause of death in women worldwide, and the number of patients and deaths is increasing each year. Approximately 3.8 million women die from CHD every year globally.
View Article and Find Full Text PDF'Bone Health-Across a Woman's Lifespan'.
Clin Endocrinol (Oxf)
January 2025
Centre for Endocrinology & Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Despite a high burden of osteoporosis and minimal trauma fractures worldwide, there is still a treatment gap in timely diagnosis and optimal treatment. There is also a lack of international consensus and guidelines on the management of bone fragility in premenopausal women. This review article provides an overview of the current understanding of factors impacting women's bone health across the adult lifespan, as well as dilemmas in the diagnosis, assessment and management of osteoporosis in premenopausal and postmenopausal women, premature ovarian insufficiency and bone health following breast cancer.
View Article and Find Full Text PDFEndogenous sex hormone levels are associated with the revised Framingham Stroke Risk Profile in postmenopausal women: a longitudinal study in a Swedish cohort.
BMC Endocr Disord
January 2025
Family medicine, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Box 454, Göteborg, 40530, Sweden.
Background: Endogenous sex hormones in postmenopausal women have been associated with risk of cardiovascular diseases. The aim of this study was to determine the association between endogenous sex hormones and the revised Framingham Stroke Risk Profile (rFSRP) in postmenopausal women.
Methods: This is an observational cross-sectional study on the Vara-Skövde cohort, a Swedish population-based study for longitudinal surveillance of the development and progress of type 2 diabetes and hypertension.
Impact of Daily High Ergosterol Intake for 14 Weeks in Ovariectomized Rats on Cholesterol and Vitamin D Biosynthesis Pathways.
Biol Pharm Bull
January 2025
Division of Bio-Analytical Chemistry, Faculty of Medical Technology, Niigata University of Pharmacy and Medical and Life Sciences, 265-1 Higashijima, Akiha-ku, Niigata 956-8603, Japan.
Postmenopausal women are at a higher risk of developing dyslipidemia and osteoporosis due to estrogen deficiency, necessitating regular vitamin D supplementation and the use of cholesterol inhibitors, respectively, to prevent these conditions. Despite current treatments, alternatives are needed to address both conditions simultaneously. Ergosterol, a precursor of vitamin D, is a fungal sterol converted to brassicasterol by 7-dehydrocholesterol reductase, a cholesterol biosynthesis enzyme that converts 7-dehydrocholesterol (a precursor of vitamin D) into cholesterol.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!